imugene her-vaxx video asx: imu | an emerging leader in cancer immuno-oncology
Published 5 years ago • 1K plays • Length 4:49Download video MP4
Download video MP3
Similar videos
-
4:14
imugene (asx:imu) doses first patient in iv arm of phase 1 oncarlytics trial targeting solid cancers
-
26:23
imugene (asx:imu) presentation, nwr virtual healthcare conference
-
2:24
her-vaxx study investigator, dr marina maglakelidze
-
5:04
imugene (asx:imu) | jmm & éthica capital innovation interview \ may 2024
-
7:40
imugene limited (asx: imu) emergence 2024: presentation by leslie chong, managing director and ceo
-
15:06
imugene (asx:imu) | jmm & éthica capital innovation & investment insights | may 2024
-
4:53
imugene featured on fox business's 'trending today' as a trailblazer in the biotechnology industry.
-
5:15
imugene featured on behind the scenes with host laurence fishburne.
-
20:11
interview with the cf33 oncolytic virus inventor - imugene (imu)
-
4:27
imugene pd1 vaxx 1080p
-
4:52
'the why' | imugene, developing cancer immunotherapies asx: imu
-
32:27
imugene limited (asx:imu) swot analysis | 21st century oncology
-
18:46
imugene (asx: imu) presentation | nwr virtual healthcare conference
-
2:59
imugene: a worldwide license to attack blood cancer
-
5:20
first patient in nextherizon phase 2 clinical trial
-
4:07
combination car t oncolytic virus immunotherapy kills tumors
-
6:16
imugene's new cancer therapy cd19 (oncarlytics) considered the 'holy grail'
-
4:53
imugene (asx: imu) featured on fox business 'trending today' - trailblazers in biotech
-
6:25
imugene (asx: imu)
-
5:30
imugene releases final data from phase 2 her vaxx study